Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by PoorOpinionon Feb 27, 2019 1:34pm
126 Views
Post# 29418749

RE:RE:RE:What risks might their be to NASH trial failing?

RE:RE:RE:What risks might their be to NASH trial failing?I would go to the Dec2018 fda guidance doc (that's still in the discussion phase)

https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM627376.pdf

and look at the first paragraph in III General Considerations

"Splitting NAFLD into three successive stages (NAFL, noncirrhotic NASH, and NASH with cirrhosis) can provide sponsors a convenient conceptual framework to identify areas of potential future drug development. At this time, because patients’ NAFL can exist for many years and may not progress to NASH, it may be challenging to demonstrate a favorable benefit-risk profile of pharmacological treatment(s) in NAFL patients. Therefore, NAFL treatment may be better addressed by interventions such as diet and exercise. "

I would put liver fat ALONE into this early stage of disease progression. So alone the FDA sees it as "challenging to develop pharma treatments for this stage of the disease. I'll be looking for outcomes along the lines of Intercept's either NASH resolution or fibrosis reduction for the results to be exciting, hopefully better than Intercept's


SPCEO1 wrote: It is not much but perhaps one of our more science minded freinds will comment on it if there is anything worth saying about it.

stockman75 wrote: sounds good. No idea what it really means! 




Bullboard Posts